表紙
市場調查報告書
商品編碼
1063704

前蛋白轉化酶枯草溶菌素9的全球市場:產業分析,趨勢,市場規模,及預測(∼2027年)

Proprotein Convertase Subtilisin/Kexin Type 9 Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027

出版日期: | 出版商: Infinium Global Research (IGR) | 英文 100 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球前蛋白轉化酶枯草溶菌素9的市場規模在2021年∼2027年的預測期間中預計將以9%的年複合成長率成長。

本報告提供全球前蛋白轉化酶枯草溶菌素9市場調查,提供市場概要,市場規模和預測,趨勢,成長要素及阻礙因素,產品·用途·各地區的分析等全面性資訊。

目錄

第1章 序文

  • 報告的說明
  • 調查方法
  • 研究途徑

第2章 摘要整理

  • 前蛋白轉化酶枯草溶菌素9市場概況
  • 前蛋白轉化酶枯草溶菌素9市場預測
  • 前蛋白轉化酶枯草溶菌素9市場,地區的亮點

第3章 全球前蛋白轉化酶枯草溶菌素9市場概要

  • 簡介
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • COVID-19對前蛋白轉化酶枯草溶菌素9市場的影響分析
  • 波特的五力分析
  • IGR:成長矩陣分析
    • IGR:各產品的成長矩陣分析
    • IGR:各用途的成長矩陣分析
    • IGR:各地區的成長矩陣分析
  • 前蛋白轉化酶枯草溶菌素9市場價值鏈分析

第4章 前蛋白轉化酶枯草溶菌素9市場宏觀指標分析

第5章 各產品的全球前蛋白轉化酶枯草溶菌素9市場

  • SX-PCK9
  • K-312
  • DCRPCSK-9
  • LY3015014
  • 其他

第6章 各用途的全球前蛋白轉化酶枯草溶菌素9市場

  • 循環系統疾病
  • 均質連接型家族性高膽固醇血症
  • 肝疾病
  • METABOLIC INC.·綜合病徵
  • 其他

第7章 各地區的全球前蛋白轉化酶枯草溶菌素9市場(2021年∼2027年)

  • 北美
    • 北美的前蛋白轉化酶枯草溶菌素9市場:各產品
    • 北美的前蛋白轉化酶枯草溶菌素9市場:各用途
    • 北美的前蛋白轉化酶枯草溶菌素9市場:各國
  • 歐洲
    • 歐洲的前蛋白轉化酶枯草溶菌素9市場:各產品
    • 歐洲的前蛋白轉化酶枯草溶菌素9市場:各用途
    • 歐洲的前蛋白轉化酶枯草溶菌素9市場:各國
  • 亞太地區
    • 亞太地區的前蛋白轉化酶枯草溶菌素9市場:各產品
    • 亞太地區的前蛋白轉化酶枯草溶菌素9市場:各用途
    • 亞太地區的前蛋白轉化酶枯草溶菌素9市場:各國
  • 其他地區
    • 其他地區的前蛋白轉化酶枯草溶菌素9市場:各產品
    • 其他地區的前蛋白轉化酶枯草溶菌素9市場:各用途
    • 其他地區的前蛋白轉化酶枯草溶菌素9市場:各子地區

第8章 企業簡介和競爭情形

  • 全球前蛋白轉化酶枯草溶菌素9市場競爭情形
  • 企業簡介
    • Pfizer Inc
    • Novartis AG
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
    • Ensemble Therapeutics Corp
    • The Medicines Company
    • Regeneron Pharmaceuticals In
    • AFFiRiS AG
    • BioLingus AG
    • Catabasis Pharmaceuticals Inc
    • Bioleaders Corp
目錄
Product Code: HC08745

The report on the global proprotein convertase subtilisin/kexin type 9 market provides qualitative and quantitative analysis for the period from 2019 to 2027. The report predicts the global proprotein convertase subtilisin/kexin type 9 market to grow with a CAGR of 9% over the forecast period from 2021-2027. The study on proprotein convertase subtilisin/kexin type 9 market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2019 to 2027.

The report on proprotein convertase subtilisin/kexin type 9 market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global proprotein convertase subtilisin/kexin type 9 market over the period of 2019 to 2027. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global proprotein convertase subtilisin/kexin type 9 market over the period of 2019 to 2027. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

  • The increasing frequency of atherosclerotic cardiovascular diseases and familial hypercholesterolemia is expected to drive market growth in the upcoming years

2) Restraints

  • The high cost of pcsk9 inhibitors is likely to hamper market growth

3) Opportunities

  • Various technological advancements, such as the development of novel drug classes will create opportunities for the market to grow.

Research Methodology

A) Primary Research

Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include

  • 1. Key Opinion Leaders associated with Infinium Global Research
  • 2. Internal and External subject matter experts
  • 3. Professionals and participants from the industry

Our primary research respondents typically include

  • 1. Executives working with leading companies in the market under review
  • 2. Product/brand/marketing managers
  • 3. CXO level executives
  • 4. Regional/zonal/ country managers
  • 5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include

  • 1. Company reports and publications
  • 2. Government/institutional publications
  • 3. Trade and associations journals
  • 4. Databases such as WTO, OECD, World Bank, and among others.
  • 5. Websites and publications by research agencies

Segment Covered

The global proprotein convertase subtilisin/kexin type 9 market is segmented on the basis of product, and application.

The Global Proprotein Convertase Subtilisin/kexin Type 9 Market by Product

  • SX-PCK9
  • K-312
  • DCRPCSK-9
  • LY3015014
  • Others

The Global Proprotein Convertase Subtilisin/kexin Type 9 Market by Application

  • Cardiovascular Disease
  • Homozygous Familial Hypercholesterolemia
  • Liver Disease
  • Metabolic Syndrome
  • Others

Company Profiles

The companies covered in the report include

  • Pfizer Inc
  • Novartis AG
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Ensemble Therapeutics Corp
  • The Medicines Company
  • Regeneron Pharmaceuticals In
  • AFFiRiS AG
  • BioLingus AG
  • Catabasis Pharmaceuticals Inc
  • Bioleaders Corp

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the proprotein convertase subtilisin/kexin type 9 market.

2. Complete coverage of all the segments in the proprotein convertase subtilisin/kexin type 9 market to analyze the trends, developments in the global market and forecast of market size up to 2027.

3. Comprehensive analysis of the companies operating in the global proprotein convertase subtilisin/kexin type 9 market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.

4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

Table of Contents

1. Preface

  • 1.1. Report Description
  • 1.2. Research Methods
  • 1.3. Research Approaches

2. Executive Summary

  • 2.1. Proprotein Convertase Subtilisin/kexin Type 9 Market Highlights
  • 2.2. Proprotein Convertase Subtilisin/kexin Type 9 Market Projection
  • 2.3. Proprotein Convertase Subtilisin/kexin Type 9 Market Regional Highlights

3. Global Proprotein Convertase Subtilisin/kexin Type 9 Market Overview

  • 3.1. Introduction
  • 3.2. Market Dynamics
    • 3.2.1. Drivers
    • 3.2.2. Restraints
    • 3.2.3. Opportunities
  • 3.3. Analysis of COVID-19 impact on the Proprotein Convertase Subtilisin/kexin Type 9 Market
  • 3.4. Porter's Five Forces Analysis
  • 3.5. IGR-Growth Matrix Analysis
    • 3.5.1. IGR-Growth Matrix Analysis by Product
    • 3.5.2. IGR-Growth Matrix Analysis by Application
    • 3.5.3. IGR-Growth Matrix Analysis by Region
  • 3.6. Value Chain Analysis of Proprotein Convertase Subtilisin/kexin Type 9 Market

4. Proprotein Convertase Subtilisin/kexin Type 9 Market Macro Indicator Analysis

5. Global Proprotein Convertase Subtilisin/kexin Type 9 Market by Product

  • 5.1. SX-PCK9
  • 5.2. K-312
  • 5.3. DCRPCSK-9
  • 5.4. LY3015014
  • 5.5. Others

6. Global Proprotein Convertase Subtilisin/kexin Type 9 Market by Application

  • 6.1. Cardiovascular Disease
  • 6.2. Homozygous Familial Hypercholesterolemia
  • 6.3. Liver Disease
  • 6.4. Metabolic Syndrome
  • 6.5. Others

7. Global Proprotein Convertase Subtilisin/kexin Type 9 Market by Region 2021-2027

  • 7.1. North America
    • 7.1.1. North America Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
    • 7.1.2. North America Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
    • 7.1.3. North America Proprotein Convertase Subtilisin/kexin Type 9 Market by Country
  • 7.2. Europe
    • 7.2.1. Europe Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
    • 7.2.2. Europe Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
    • 7.2.3. Europe Proprotein Convertase Subtilisin/kexin Type 9 Market by Country
  • 7.3. Asia-Pacific
    • 7.3.1. Asia-Pacific Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
    • 7.3.2. Asia-Pacific Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
    • 7.3.3. Asia-Pacific Proprotein Convertase Subtilisin/kexin Type 9 Market by Country
  • 7.4. RoW
    • 7.4.1. RoW Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
    • 7.4.2. RoW Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
    • 7.4.3. RoW Proprotein Convertase Subtilisin/kexin Type 9 Market by Sub-region

8. Company Profiles and Competitive Landscape

  • 8.1. Competitive Landscape in the Global Proprotein Convertase Subtilisin/kexin Type 9 Market
  • 8.2. Companies Profiles
    • 8.2.1. Pfizer Inc
    • 8.2.2. Novartis AG
    • 8.2.3. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
    • 8.2.4. Ensemble Therapeutics Corp
    • 8.2.5. The Medicines Company
    • 8.2.6. Regeneron Pharmaceuticals In
    • 8.2.7. AFFiRiS AG
    • 8.2.8. BioLingus AG
    • 8.2.9. Catabasis Pharmaceuticals Inc
    • 8.2.10. Bioleaders Corp